IDEAYA Q2 2026: $1.24B Cash Runway, Darovasertib NDA on Track, Pipeline Momentum Builds
IDYA sits 63% above its 52-week low of $22.09.
Summary
IDEAYA's Q2 2026 filing reveals $1.24B in cash, positive darovasertib data, and an NDA submission on track for H2 2026. R&D spending has risen sharply as the pipeline advances, yet the balance sheet stays robust following a $345M follow-on offering.
Key Events · Earnings and Guidance · IDYA
-
Darovasertib NDA on Track
Positive Phase 2/3 OptimUM-02 data supports an NDA submission in H2 2026 for metastatic uveal melanoma, with the FDA's Real-Time Oncology Review program being utilized.
-
Strong Cash Position
Cash, equivalents, and marketable securities totaled $1.24 billion as of June 30, 2026, bolstered by a $345 million follow-on offering that closed in June.
-
R&D Spending Surge
Research and development expenses rose 41% year-over-year to $204.4 million for H1 2026, driven by the advancement of darovasertib, IDE849, IDE034, and other programs.
-
New Collaborations
During the quarter, clinical supply agreements were entered with AstraZeneca for IDE849 plus Imfinzi, and with Roche for IDE892 plus a pan-RAS inhibitor.
Analysis · IDYA · Life Sciences
A robust $1.24 billion in cash and equivalents gives IDEAYA a runway well beyond 12 months, according to its Q2 2026 10-Q. The quarter's highlight was positive Phase 2/3 data for lead asset darovasertib, keeping an NDA submission on schedule for the second half of 2026. Reflecting broad pipeline progress—including new clinical collaborations with AstraZeneca and Roche—R&D spending jumped 41% year-over-year to $204.4 million for the first half. A $345 million follow-on offering closed in June further fortified the balance sheet. While the net loss widened to $112.5 million for the quarter on increased clinical activity, the cash position and upcoming catalysts leave the investment thesis intact.
At the time of this filing, IDYA was trading at $36.11 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.4B. The 52-week trading range was $22.09 to $40.58. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.